CAI
Caris Life Sciences, Inc.NASDAQHealthcare$19.29+0.84%ClosedMarket Cap: $5.45B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
55.87
P/S
6.71
EV/EBITDA
1196.99
DCF Value
$-13.67
FCF Yield
0.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
66.4%
Operating Margin
5.6%
Net Margin
-8.4%
ROE
25.0%
ROA
-6.2%
ROIC
4.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $292.9M | 75.4% | $52.4M | $82.0M | $0.28 | — |
| FY 2025 | $812.0M | 66.4% | $45.1M | $-538.0M | $-1.90 | — |
| Q3 2025 | $216.8M | 68.0% | $32.6M | $24.3M | $0.08 | — |
| Q2 2025 | $181.4M | 62.7% | $18.0M | $-71.8M | $-1.87 | — |
| Q1 2025 | $120.9M | 47.2% | $-58.0M | $-102.6M | $-0.40 | — |
| FY 2024 | $412.3M | 43.4% | $-257.1M | $-281.9M | $-2.70 | — |
| Q2 2024 | $100.0M | 37.5% | $67.0M | $-66.2M | $-0.35 | — |
| Q1 2024 | $80.7M | 32.4% | $-92.2M | $-111.0M | $-0.53 | — |
| FY 2023 | $306.1M | 29.2% | $-319.6M | $-341.4M | $-1.82 | — |
| FY 2022 | $258.5M | 31.0% | $-315.8M | $-320.8M | $-1.57 | — |
| Q3 2021 | $100.8M | 53.6% | $66.4M | $51.2M | $2.92 | — |
| Q2 2021 | $85.7M | 50.0% | $50.8M | $37.9M | $2.17 | — |